Cerus Corporation (CERS)
| Market Cap | 877.41M |
| Revenue (ttm) | 172.97M |
| Net Income (ttm) | -49.20M |
| Shares Out | 176.90M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 944,281 |
| Open | 5.01 |
| Previous Close | 5.12 |
| Day's Range | 4.89 - 5.06 |
| 52-Week Range | 4.38 - 8.06 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 9.59 (+93.3%) |
| Earnings Date | May 5, 2022 |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ...
Financial Performance
In 2021, Cerus's revenue was $159.52 million, an increase of 39.62% compared to the previous year's $114.25 million. Losses were -$54.37 million, -9.16% less than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CERS stock is "Buy." The 12-month stock price forecast is 9.59, which is an increase of 93.35% from the latest price.
News
Does Cerus (CERS) Have the Potential to Rally 89% as Wall Street Analysts Expect?
The mean of analysts' price targets for Cerus (CERS) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidanc...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2022. Recent developments and highlights include: First quarter...
Cerus Corporation Announces New Manufacturing and Supply Agreement With Fresenius Kabi For INTERCEPT Blood System Sets
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets. This new...
Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets. Under...
Cerus Corporation to Release First Quarter 2022 Financial Results on May 5, 2022
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock m...
Cerus Corporation to Participate at the Cowen 42nd Annual Health Care Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' chief financial officer, is scheduled to participate at the Cowen 42nd Annual Health Care C...
Does Cerus (CERS) Have the Potential to Rally 90% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 90.5% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive t...
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021. Recent developments and highlights incl...
Cerus Corporation to Release Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the ...
Cerus Corporation to Participate in Upcoming Virtual Investor Conferences
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conferen...
Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Busines...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2021, provided product revenue guidance for 2022 and p...
4 Growth Stocks Under $10 to Buy for 2022
Growth stocks tend to perform well when the economy starts to pick up. Nissan Motor (NSANY), Arko Corp. (ARKO), Arcos Dorados (ARCO) and Cerus (CERS) look well-poised to grow.
How Much Upside is Left in Cerus (CERS)? Wall Street Analysts Think 44%
The consensus price target hints at a 43.9% upside potential for Cerus (CERS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revi...
3 Beaten-Down Medical Product Stocks to Buy on a Turnaround in 2022
Here are some medical product stocks from the MedTech sector - Quidel (QDEL), Cerus (CERS) and NextGen Healthcare (NXGN) - which might be witnessing a turnaround in 2022 and be solid investment options.
Wall Street Analysts Think Cerus (CERS) Could Surge 35%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 35.4% in Cerus (CERS). While the effectiveness of this highly sought-after metric is questionable, the positive t...
Cerus Corporation to Participate in Stephens Annual Investment Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' chief financial officer, is scheduled to participate in the Stephens Annual Investment Conf...
Cerus Corporation to Participate in Stifel 2021 Virtual Healthcare Conference
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial o...
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of 30.00% and 14.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation Announces Record Third Quarter 2021 Financial Results and Raises Full-Year Product Revenue Guidance
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2021. Recent developments and highlights include: Third qua...
Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus Corporation to Release Third Quarter 2021 Financial Results on November 2, 2021
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the sto...
Undervalued Stocks That Catherine Wood and Ron Baron Agree On
According to the GuruFocus Scoreboard, where users can sort investing gurus based on their fund performances over specific periods of time, the gurus that posted the highest gains during the most recent...
Cerus Corporation Applauds FDA Requirements Effective Today to Safeguard the U.S. Platelet Supply
CONCORD, Calif.--(BUSINESS WIRE)--Today marks the effective date for the U.S. Food and Drug Administration's (FDA) final guidance document on bacterial risk control strategies for platelet collection an...